Antiphospholipid (Hughes) syndrome and atheroma

Lupus

Volumn 15, Issue 11_suppl, 2006, Pages 55-58

  Davies, R J ^a   Sangle, S R ^a   Khamashta, M A ^a   D'Cruz, D P ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

ankle brachial index; antiphospholipid syndrome; atheroma

Indexed keywords

PHOSPHOLIPID ANTIBODY; PHOSPHOLIPID BINDING PROTEIN;

ANKLE BRACHIAL INDEX; ANTIPHOSPHOLIPID SYNDROME; ATHEROMA; CELL ACTIVATION; ENDOTHELIUM CELL; HUMAN; MORBIDITY; PREGNANCY; PRIORITY JOURNAL; REVIEW;

EID: 84994376904     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203306071669     Document Type: Review

References (43)

1. Hughes GRV., The antiphospholipid syndrome: Ten years on. Lancet 1993; 342: 341-344.
2. Ross R., The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 326: 801-809.
3. Ross R., Atherosclerosis-an inflammatory disease. N Eng J Med 1999; 340: 115-126.
4. Hunt BJ., The endothelium in atherogenesis. Lupus 2000; 9: 189-193.
5. Steinberg D., Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963-20966.
6. Brown MS, Goldstein JL., Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. A Rev Biochem 1983; 52: 223-261.
7. Henriksen T, Mahoney EM, Steinburg D., Enhanced macrophage degradation of low density lipoproteins previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci USA 1981; 78: 6499-6503.
8. Henriksen T, Mahoney EM, Steinburg D., Enhanced macrophage degradation of biologically modified low density lipoprotein. Arteriosclerosis 1983; 3: 149-159.
9. Vaarala O, Manttari M, Manninen V, et al.Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23-27.
10. Cervera R., Coronary and valvular syndromes and antiphospholipid antibodies. Thrombosis Research 2004; 114: 501-507.
11. Sletnes KE, Smith P, Abdelnoor M, Arnesen H, Wisloff F., Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction and non-haemorrhagic stroke. Lancet 1992; 339: 451-453.
12. Simantov R, LaSala JM, Lo SK, et al.Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 2211-2219.
13. Del Papa N, Guidali L, Sala A, et al.Endothelial cells as targets for antiphospholipid antibodies. Arthritis Rheum 1997; 40: 551-561.
14. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN., Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99: 1997-2002.
15. Hasunuma Y, Matsura E, Makita Z, Katahira T, Nishi S, Koike T., Involvement of ß2 glycoprotein I and anticardiolipin antibodies in oxidatively modified low density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 569-574.
16. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho KND, Palosuo T., Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 2: 923-925.
17. Maggie E, Perani G, Falaschi F, et al.Autoantibodies against oxidized LDL in patients with coronary disease. Presse Med 1994; 23: 1158-1162.
18. Vaarala O., Antibodies to oxidized LDL. Lupus 2000; 9: 202-205.
19. Roubey RAS., Immunology of antiphospholipid syndrome. Arthritis Rheum 1996; 39: 1444-1456.
20. Blank M, Shoenfeld Y, Cabilly S, et al.Prevention of experimental antiphospholipid syndrome and endothelial cell activation by peptides. Proc Natl Acad Sci 1999; 96: 5164-5168.
21. George J, Harats D, Gilburd B, et al.Immunolocalisation of β2-glycoprotein I (Apolipoprotein H) to human atherosclerotic plaques. Circulation 1999; 99: 2227-2230.
22. Matsuura E, Lopez LR., Are oxidized LDL/β2-glycoprotein I complexes pathogenic antigens in autoimmune mediated atherosclerosis? Clin Dev Immunol 2004; 11: 103-111.
23. George J, Afek A, Gilburd B, et al.Induction of early atherosclerosis in LDL deficient mice immunized with β2-glycoprotein I. Circulation 1998; 98: 1108-1115.
24. Medina G, Casaos D, Jara LJ, et al.Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 2003; 62: 607-610.
25. Ames PR, Margarita A, Delgado Alves J, et al.Anticardiolipin antibody titre and plasma homocysteine level independently predict intimal media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 2002; 11: 208-214.
26. Ames PR, Margarita A, Sokoll KB, et al.Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 2005; 64: 315-317.
27. Charakida M, Halcox JP, Sangle S, et al.Preclinical atherosclerotic phenotype in patients with primary antiphospholipid syndrome. Rheumatology 2006 (abstract).
28. Baron M, D'Cruz D, Khamashta MA, Hughes GRV., Prevalence of abnormal ankle-brachial index in primary antiphospholipid syndrome. Ann Rheum Dis 2005; 64: 144-146.
29. Christodoulou C, Zain M, Bertolaccini ML, et al.The prevalence of an abnormal ankle-brachial index in antiphospholipid syndrome patients with pregnancy loss but without thrombosis: a controlled study. Ann Rheum Dis 2000; 65: 683-684.
30. Sangle SR, D'Cruz DP, Jan W, et al.Renal artery stenosis in antiphospholipid syndrome and hypertension. Ann Rheum Dis 2003; 62: 999-1002.
31. Sangle S, Jan W, Lau I, Bennet A, Hughes GRV, D'Cruz DP., Coeliac artery stenosis and antiphospholipid (Hughes') syndrome/antiphospholipid antibodies. Clin Exp Rheumatol 2006; 24: 349.
32. Sipek-Dornicar A, Hojnik M, Bozic B, Vizjak A, Rozman B, Ferluga D., Clinical presentation and vascular histopathology in autopsied patients with systemic lupus erythematosus and anticardiolipin antibodies. Clin & Exper Rheum 2002; 20: 335-342.
33. Kojima E, Naito K, Iwai M, Hirose Y, Isobe K, Takano K., Antiphospholipid syndrome complicated by thrombosis of the superior mesenteric artery, co-existence of smooth muscle hyperplasia. Intern Med 1997; 36: 528-531.
34. Meroni PL, Borghi MO, Raschi E, et al.Inflammatory response and the endothelium. Thrombosis Research 2004; 114: 329-334.
35. Petri M., Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996; 5 (Suppl 1): S16-S22.
36. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, et al.Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406.
37. Ferrara DE., Inhibition of thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003: 48; 3272-3279.
38. Cuadrado MJ, Buendia P, Aguirre A, et al.Effect of fluvastatin on monocyte tissue factor expression in primary antiphospholipid syndrome. Preliminary results of an in vivo study. Arthritis Rheum 2005; 52: S263 (613).
39. Allison AC, Eugui EM., Mycophenolate mofetil and it's mechanism of action. Immunopharm 2000; 47: 85-118.
40. Romero F, Rodriguez-Iturbe B, Pons H, et al.Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit. Atherosclerosis 2000; 152: 127-133.
41. Greenstein SM, Sun S, Calderon TM, et al.Mycophenolate mofetil treatment reduces atherosclerosis in the cholesterol-fed rabbit. J Vasc Res 2000; 91: 123-129.
42. Kobashigawa J, Miller L, Renlund D, et al.A randomized activecontrolled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998; 66: 507-515.
43. George J, Shoenfeld Y., The antiphospholipid 'Hughes syndrome' syndrome: a cross roads of autoimmunity and atherosclerosis. Lupus 1997; 6: 559-560.